P462: IDENTIFICATION OF TARGETED THERAPIES DIRECTED TO ACUTE MYELOID LEUKEMIA MINIMAL RESIDUAL DISEASE

Autor: N. van Gils, F. Kessler, M. Broux, F. Denkers, S. Demeyer, J. Cools, D. C. De Leeuw, J. Janssen, L. Smit

Publikováno v: HemaSphere, Vol 6, Pp 361-362 (2022)

Externí odkaz: https://doaj.org/article/1154ef6cfadf4cc39991a1b35f4816b7

IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival

Autor: Walter Pouwels, Gerrit-Jan Schuurhuis, M Gm Roemer, Arjo P Rutten, Patrick H.N. Celie, Linda Smit, Gert J. Ossenkoppele, H Jmp Verhagen, D C de Leeuw, Fedor Denkers

Publikováno v: Verhagen, H J M P, de Leeuw, D C, Roemer, M G M, Denkers, F, Pouwels, W, Rutten, A, Celie, P H, Ossenkoppele, G J, Schuurhuis, G J & Smit, L 2014, ' IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival ', Cell death & disease, vol. 5, e1300 . https://doi.org/10.1038/cddis.2014.268
Cell Death & Disease
Cell death & disease, 5:e1300. Nature Publishing Group

Despite high remission rates after chemotherapy, only 30-40% of acute myeloid leukemia (AML) patients survive 5 years after diagnosis. This extremely poor prognosis of AML is mainly caused by treatment failure due to chemotherapy resistance. Chemothe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a40736d879e90917d0745f9a05fbc4b
https://research.vumc.nl/en/publications/9fb7d6f1-d7d5-4911-9506-82e752d24c61